COVI-VAC for SARS-CoV-2 (COVID-19)
The COVID-19 pandemic continues to spread in the U.S and new strains of the virus are emerging. COVI-VAC is a single-dose, intranasal, live-attenuated vaccine against COVID-19, generated using Codagenix’s proprietary deoptimization technology. COVI-VAC was safe and protective in the gold standard animal model after just one dose and is currently being evaluated in a Phase I clinical trial. Unlike many other COVID-19 vaccines, COVI-VAC is designed to produce immunity against all SARS-CoV-2 proteins, not just the spike surface protein, positioning it to protect against a range of SARS-CoV-2 strains. Live-attenuated vaccines like COVI-VAC elicit a robust immune response and are associated with long lasting cellular immunity.
Wildtype “normal” virus
Our vaccine virus, COVI-VAC
To meet the vast global demand for immunization against COVID-19, vaccines must be easily scaled for mass production and easy to administer. Codagenix meets this demand in several ways:
- The Codagenix vaccine can be grown easily in cell culture, is scalable and can be produced in quantities sufficient to make a significant contribution to meeting global needs;
- Intranasal administration does not require needles or specially trained healthcare providers and is thus uniquely suited for a mass immunization campaign; and
- Codagenix is partnered with the Serum Institute of India, the largest vaccine manufacturer in the world by doses sold, for vaccine production and global distribution. Partnering with the Serum Institute offers Codagenix unrivaled manufacturing capacity and expertise.
These features, combined with excellent safety and efficacy data seen in animals, positions COVI-VAC as a major contender in the fight against COVID-19.